PartitionBio Ltd Information

PartitionBio is a biotechnology company developing a non-viral intracellular delivery platform based on liquid-liquid phase separation (LLPS) and biomolecular condensates. Our lead product, BubbleFect™, is a room-temperature stable, non-lipid reagent designed for simple bench-top use without specialist equipment or cold chain requirements. Unlike lipid-based delivery methods, BubbleFect maintains high cell viability — making it particularly well suited to sensitive and hard-to-transfect cell types including hiPSCs, primary cells and suspension cells. BubbleFect delivers a broad range of macromolecular cargos — including mRNA, CRISPR/RNP, plasmid DNA, proteins and ASOs — across diverse cell types and applications spanning gene therapy, functional genomics, RNA delivery and protein delivery. BubbleFect is used by 185 researchers across 99 organisations in 17 countries, including leading academic institutions, biotech companies and global pharmaceutical partners. PartitionBio is based at Unity Campus, Cambridge, UK.